Melane Sampson, Author at BioTuesdays

Developments

Canopy Growth affiliate receives Health Canada cannabis license

Canopy Rivers’ (TSXV:RIV) portfolio company, Radicle Medical Marijuana, received a production and sales licence from Health Canada to supply and sell finished cannabis products for both the medical and adult-use market...

November 19, 2018

Developments

Constellation Brands closes $5-billion investment in Canopy Growth

Constellation Brands (NYSE:STZ) closed its $5-billion (Canadian) investment in Canopy Growth (TSX:WEED; NYSE:CGC) following approval by Canopy shareholders and all regulatory agencies, including the Canadian government...

November 1, 2018

Markets

Leerink cuts Clovis Oncology PT to $22 from $30

Leerink lowered its price target for Clovis Oncology (NASDAQ:CLVS) to $22 from $30 but maintained its “market perform” rating after the company reported third quarter results. The stock closed at $16.61 on Oct. 30...

October 31, 2018

Developments

Lobo Cube DNA testing device for safer cannabis use gaining major media attention

An Oct. 26 article on the Washington Post web site discusses job openings in Canada’s legalized cannabis sector, highlighting an Ontario government policy advisor who left his job to join Lobo Genetics as its director...

October 26, 2018

Executive Moves

Breath Therapeutics names Peter Shadday as chief commercial officer

Closely-held Breath Therapeutics appointed Peter Shadday as chief commercial officer to lead the company’s market access activities and product commercialization.

October 17, 2018

Markets

Leerink cuts Immune Design to MP; PT to $3 from $7

Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY...

October 12, 2018

Developments

CHF Solutions in collaboration with NI Medical on fluid overload

CHF Solutions (NASDAQ:CHFS) and NI Medical are collaborating to explore potential clinical synergies between CHF’s Aquadex FlexFlow System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume...

October 11, 2018

Developments

iBio and CC-Pharming hold first design and strategy meeting

iBio (NYSE American:IBIO) and CC-Pharming of Beijing are holding a four-day design and strategic planning meeting at iBio’s development and manufacturing facility in Bryan, Texas. The meeting initiates the first stage...

October 2, 2018

Executive Moves

3DS names Sherif Louis as CEO

3D Signatures (TSX:DXD) appointed Sherif Louis, as the company's chief executive officer.

September 25, 2018

Developments

IntelGenx posts successful bioequivalence study results for RIZAPORT

IntelGenx (TSXV:IGX; OTCQX:IGXT) reported successful results from a bioequivalence study for RIZAPORT, its proprietary anti-migraine VersaFilm product, demonstrating that RIZAORT is bioequivalent to the U.S. reference...

September 24, 2018

Author - Melane Sampson

Canopy Growth affiliate receives Health Canada cannabis license

Constellation Brands closes $5-billion investment in Canopy Growth

Leerink cuts Clovis Oncology PT to $22 from $30

Lobo Cube DNA testing device for safer cannabis use gaining major media attention

Breath Therapeutics names Peter Shadday as chief commercial officer

Leerink cuts Immune Design to MP; PT to $3 from $7

CHF Solutions in collaboration with NI Medical on fluid overload

iBio and CC-Pharming hold first design and strategy meeting

3DS names Sherif Louis as CEO

IntelGenx posts successful bioequivalence study results for RIZAPORT

General

More